Geode Capital Management, LLC Forma Therapeutics Holdings, Inc. Transaction History

Geode Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.12 - $20.24 $667,578 - $1.9 Million	93,761 Added 15.42%	701,849 $14 Million
Q2 2022 Aug 12, 2022	BUY	$5.1 - $10.0 $223,257 - $437,760	43,776 Added 7.76%	608,088 $4.19 Million
Q1 2022 May 13, 2022	BUY	$8.34 - $14.69 $87,870 - $154,773	10,536 Added 1.9%	564,312 $5.25 Million
Q4 2021 Feb 11, 2022	BUY	$13.6 - $24.89 $835,135 - $1.53 Million	61,407 Added 12.47%	553,776 $7.87 Million
Q3 2021 Nov 12, 2021	BUY	$21.22 - $25.7 $970,220 - $1.18 Million	45,722 Added 10.24%	492,369 $11.4 Million
Q2 2021 Aug 13, 2021	BUY	$22.86 - $30.95 $305,409 - $413,492	13,360 Added 3.08%	446,647 $11.1 Million
Q1 2021 May 12, 2021	BUY	$24.58 - $42.82 $3.4 Million - $5.92 Million	138,283 Added 46.87%	433,287 $12.1 Million
Q4 2020 Feb 12, 2021	BUY	$34.9 - $51.08 $1.23 Million - $1.8 Million	35,165 Added 13.53%	295,004 $10.3 Million
Q3 2020 Nov 13, 2020	BUY	$32.95 - $50.25 $7.88 Million - $12 Million	239,144 Added 1155.56%	259,839 $13 Million
Q2 2020 Aug 13, 2020	BUY	$39.0 - $46.49 $807,105 - $962,110	20,695 New	20,695 $962,000

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.